课题基金 / 基金详情

Direct-acting antiviral initiation rates in vulnerable HIV-hepatitis C coinfected populations in Canada: Can we reach elimination?

Direct-acting antiviral initiation rates in vulnerable HIV-hepatitis C coinfected populations in Canada: Can we reach elimination?
加拿大易受艾滋病毒-丙型肝炎双重感染人群的直接抗病毒治疗起始率：我们能否实现消除？
批准号：
364600
负责人：
Saeed Sahar Z
金额：
$0.18万
依托单位：
Research Institute of the McGill University Health Centre
依托单位国家：
加拿大
项目类别：
财政年份：
2017
资助国家：
加拿大
项目状态：
已结题
起止时间：
2017-01-01 至 2018-01-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=364600&lang=en
关键词：
Cascade Of Care Co-Infection Direct Acting Antivirals Hepatitis C Hiv Treatment Rates Vulnerable Populations

项目摘要

项目成果

Saeed Sahar Z的其他基金

相似基金

相关文献

中文摘要
翻译
被称为直接作用抗病毒药物(DAA)的丙型肝炎(HCV)新药已经给治疗带来了革命性的变化，因为现在几乎每个人都可以治愈。然而，目前还不清楚是否每个人都平等地获得了这些治疗。从历史上看，丙型肝炎病毒的治疗率
英文摘要
The new hepatitis C (HCV) drugs known as direct acting antivirals (DAAs) have revolutionized treatments because now almost everyone can be cured. However, it is not clear if everyone is accessing these treatments equally. Historically, HCV treatment rates
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Breaking Barriers: Expanding Syphilis Point-of-care Testing and Immediate Treatment to Meet the Needs of Underserved Communities
The 13th Canadian Symposium on Hepatitis C Virus (CSHCV)
Advancing Syphilis Elimination: Leveraging Public Health and Academic Partnerships to Build Capacity
Liver Fibrosis: Leveraging Novel Statistical Methods to Determine Optimal Screening Strategy for People Living with Type 2 Diabetes
海外基金